» Articles » PMID: 16243265

PEGylation, Successful Approach to Drug Delivery

Overview
Specialty Pharmacology
Date 2005 Oct 26
PMID 16243265
Citations 502
Authors
Affiliations
Soon will be listed here.
Abstract

PEGylation defines the modification of a protein, peptide or non-peptide molecule by the linking of one or more polyethylene glycol (PEG) chains. This polymer is non-toxic, non-immunogenic, non-antigenic, highly soluble in water and FDA approved. The PEG-drug conjugates have several advantages: a prolonged residence in body, a decreased degradation by metabolic enzymes and a reduction or elimination of protein immunogenicity. Thanks to these favorable properties, PEGylation now plays an important role in drug delivery, enhancing the potentials of peptides and proteins as therapeutic agents.

Citing Articles

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.

Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B Signal Transduct Target Ther. 2025; 10(1):73.

PMID: 40059188 PMC: 11891339. DOI: 10.1038/s41392-024-02112-8.


Low-Dose Docetaxel Is Effective in Reducing Atherogenic Lipids and Atherosclerosis.

Choi H, Ruel I, Choi S, Iatan I, Choi S, Lee J Int J Mol Sci. 2025; 26(4).

PMID: 40003949 PMC: 11855627. DOI: 10.3390/ijms26041484.


Hydrogels from Protein-Polymer Conjugates: A Pathway to Next-Generation Biomaterials.

Alayoubi O, Poyraz Y, Hassan G, Gul S, Calhan N, Mert Sahin N Gels. 2025; 11(2).

PMID: 39996639 PMC: 11854714. DOI: 10.3390/gels11020096.


Recent advances in polymeric nanoparticles for the treatment of hepatic diseases.

Gao F, Feng X, Li X Front Pharmacol. 2025; 16:1528752.

PMID: 39925843 PMC: 11802823. DOI: 10.3389/fphar.2025.1528752.


Biomedical Metal-Organic Framework Materials: Perspectives and Challenges.

Wang A, Walden M, Ettlinger R, Kiessling F, Gassensmith J, Lammers T Adv Funct Mater. 2024; 34(43).

PMID: 39726715 PMC: 7617264. DOI: 10.1002/adfm.202308589.